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Abstract Prior searches for genetic variants (GVs) im-
plicated in initiation of cannabis use have been limited to
common single nucleotide polymorphisms (SNPs) typed in
HapMap samples. Denser SNPs are now available with the
completion of the 1000 Genomes and the Genome of the
Netherlands projects. More densely distributed SNPs are
expected to track the causal variants better. Therefore we
extend the search for variants implicated in early stages of
cannabis use to previously untagged common and low-fre-
quency variants. We run heritability, SNP and gene-based
analyses of initiation and age at onset. This is the first gen-
ome-wide study of age at onset to date. Using GCTA and a
sample of distantly related individuals from the Netherlands
Twin Register, we estimated that the currently measured
(and tagged) SNPs collectively explain 25 % of the variance
in initiation (SE = 0.088; P = 0.0016). Chromosomes 4
and 18, previously linked with cannabis use and other ad-
diction phenotypes, account for the largest amount of vari-
ance in initiation (6.8 %, SE = 0.025, P = 0.002 and 3.6 %,
SE = 0.01, P = 0.012, respectively). No individual SNP- or
gene-based test reached genomewide significance in the
initiation or age at onset analyses. Our study detected asso-
ciation signal in the currentlymeasured SNPs. A comparison
with prior SNP-heritability estimates suggests that at least
part of the signal is likely coming from previously untyped
common and low frequency variants. Our results do not rule
out the contribution of rare variants of larger effect—a
plausible source of the difference between the twin-based
heritability estimate and that from GCTA. The causal vari-
ants are likely of very small effect (i.e.,\1 % explained
variance) and are uniformly distributed over the genome in
proportion to chromosomes’ length. Similar to other com-
plex traits and diseases, detecting such small effects is to be
expected in sufficiently large samples.
Keywords Cannabis  Initiation  Age at onset 
Heritability
Introduction
Cannabis is among the drugs with the highest frequency of
(ab)use. About 1 in 5 Europeans aged 15–64 reported to
have experimented with cannabis. In the United States the
prevalence in ages 16–34 was estimated at 51.6 % (Euro-
pean Monitoring Centre for Drugs and Drug Addiction,
2012). Regular cannabis use has been associated with
health problems, including mood and anxiety disorders
(e.g., Cheung et al. 2010) and chronic bronchitis (Hall
2015; Joshi et al. 2014). Early onset and regular use during
adolescence has possible effects on cognitive functioning
(e.g., Crean et al. 2011) and predicts diminished educa-
tional (Horwood et al. 2010; Lynskey and Hall 2000) and
professional attainment (Fergusson and Boden 2008;
Volkow et al. 2014). Furthermore, recent evidence suggests
that high-potency cannabis use elevates the risk of devel-
oping psychotic disorders (Di Forti et al. 2015, 2014).
Namely, the odds of showing psychotic symptoms in in-
dividuals who declared to have ever used high-potency
Edited by Sarah Medland.
Electronic supplementary material The online version of this
article (doi:10.1007/s10519-015-9723-9) contains supplementary
material, which is available to authorized users.
& Camelia C. Minica˘
c.c.minica@vu.nl
1 Department of Biological Psychology, Vrije Universiteit
Amsterdam, Van der Boechorststraat 1, 1081 BT Amsterdam,
The Netherlands
123
Behav Genet (2015) 45:503–513
DOI 10.1007/s10519-015-9723-9
cannabis are about three times larger than in individuals
who declared to have never used cannabis during their
lifetime. The risk of showing psychotic symptoms is fur-
ther elevated if high-potency cannabis is used daily (i.e.,
OR = 5.4; P = 0.002; Di Forti et al. 2015). About 9 % of
those who initiate cannabis use progress to regular use and
abuse (e.g., Volkow et al. 2014; Budney et al. 2007). Given
the possible adverse effects on health and lifetime out-
comes and given its possible role in triggering first-episode
of psychosis, it is important to understand the causes of
individual differences in the liability to initiate cannabis
use.
Twin and family studies have shown that both genetic
and environmental factors (both shared by, and specific to,
family members) have an important role in the initiation of
cannabis use (Kendler and Prescott 1998; van den Bree
et al. 1998; Vink et al. 2010). A meta-analysis of twin
studies (Verweij et al. 2010) showed that additive genetic
factors explain nearly half the variance in liability to ini-
tiate cannabis use (i.e., 48 and 40 % of the variance, in
females and males, respectively), while the remaining
variance is accounted for—almost equally—by shared and
unshared environmental factors (both about 30 %).
Among the several attempts to identify genes that ex-
plain the heritability of initiation, a linkage study (Agra-
wal et al. 2008a) failed to identify statistically significant
associated genomic regions, although it did identify sev-
eral suggestive regions on chromosomes 18 and 1. Like-
wise, a meta-analysis by Verweij et al. (Verweij et al.
2013) combining the results of two genomewide asso-
ciation studies (GWAS) comprising about 10 000 indi-
viduals failed to detect common single nucleotide
polymorphisms (SNPs) associated with initiation. It
should be noted, however, that the association analysis by
Verweij and colleagues was limited to common (i.e.,
minor allele frequency (MAF)[ 5 %) HapMap SNPs
(Consortium 2010). With the recent completion of large
sequencing projects such as the 1000 Genomes (1000G)
(Consortium 2012) and the Genome of the Netherlands
(Boomsma et al. 2014; The Genome of the Netherlands
2014), more detailed genotypic information has become
available in large GWAS samples. Given the availability
of denser SNPs, which are expected to be in high linkage
disequilibrium (LD) with the causal variants, we aim to
extend the search for genetic variants (GVs) implicated in
initiation to previously untagged common GVs, and to
other (than common) GVs, such as low-frequency variants
(1 %\MAF\ 5 %). Such low frequency variants have
not typically passed the quality control checks. However,
the quality of imputation has been improved by recent
advances in imputation techniques (Howie et al. 2012).
This opens the door to including such GVs into a gen-
ome-wide association study.
Furthermore, to date, the approach for finding genes
underlying the heritability of cannabis initiation was to
focus on the ‘ever/never used’ dichotomy at the expense of
the age at which one initiates (i.e., age at onset). Yet, age at
onset is a complex trait (Visscher et al. 2001), subject to the
influences of both environmental and genetic factors
(Lynskey et al. 2003), and may serve as an important proxy
for heavy use. Initiation of cannabis use before age 18 is
predictive of both experimentation with other drugs
(Agrawal et al. 2006; Lynskey et al. 2006), and of escalated
drug use (e.g., Lynskey et al. 2003). Among those initiating
in adolescence the risk of progression to symptoms of
abuse and dependence is higher relative to the general
population (i.e., 17 vs. 9 %, respectively; Volkow et al.
2014). Given its relevance as a predictor for escalated use,
our second aim is to perform a genomewide search for GVs
that give rise to individual differences in age at onset. To
model age at onset as a function of genotype we will apply
statistical methods based on survival analysis. This ap-
proach utilizes all available information on the age at onset
among initiateds and takes into account the censored nature
of the observations collected in those who did not initiate at
the time they were last seen (i.e., they might initiate at a
later time point). The approach is expected to show supe-
rior power relative to an analysis of the ‘‘ever-never’’ di-
chotomy or an analysis restricted to those who initiated
(see e.g. Kiefer et al. 2013). To our knowledge, a geno-
mewide survival analysis of age at onset of cannabis use
has not yet been reported.
The outline of the paper is as follows. First, we estimate
the amount of variance in initiation of cannabis use ex-
plained collectively by the currently measured SNPs. The
purpose of such analysis is to obtain an indication of the
total signal in the measured (and tagged) SNPs without
identifying individual SNPs. Second, we conduct SNP-
based association analyses of initiation and age at onset.
Our primary focus is on identifying genes tagged by the
SNPs, relevant to our traits. Therefore, next, we incorpo-
rate these SNP-based results in two gene-based analyses.
These analyses are exploratory, i.e., conducted
genomewide.
All analyses are performed in a sample of Dutch
families from the Netherlands Twin Register (NTR). To
maximize statistical power, imputation of genotypes in the
NTR sample was based on two alternative reference pan-
els: the 1000G Phase 1 project reference panel (Consortium
2012) and the reference panel generated by the Genome of
the Netherlands (GoNL) project (Boomsma et al. 2014;
The Genome of the Netherlands 2014). The GoNL refer-
ence panel was derived by sequencing the whole genome
of 250 trio-Dutch families and matches therefore the
ancestral background of our sample. The GoNL panel is
expected to facilitate imputation of variants which are
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specific to the Dutch population (Boomsma et al. 2014).
Furthermore, the use of the GoNL panel is expected to
result in higher imputation accuracy relative to the 1000G
panel, especially for low frequency GVs (MAF\ 5 %)
(The Genome of the Netherlands 2014). Such increased
accuracy is expected to increase the statistical power to
capture the signal in the measured GVs.
Materials and methods
Phenotypes
The phenotypic data were obtained in the longitudinal
surveys on lifestyle, health, and personality of the NTR
(e.g., Boomsma et al. 2002, 2006). The study protocols
were approved by the Central Ethics Committee on Re-
search Involving Human Subjects of the VU University
Medical Center, Amsterdam. All participants provided in-
formed consent. The study in young twins was approved
also by the Central Committee on Research Involving
Human Subjects. More details regarding the phenotyping
in the NTR study can be found elsewhere (van Beijster-
veldt et al. 2013; Willemsen et al. 2013).
Initiation of Cannabis use (‘ever/never’)
Initiation was assessed by a multiple choice question (i.e.,
‘‘At which age did you experiment with cannabis for the
first time?’’) in the NTR surveys 1993, 1995, 2000, and by
an open-ended question (‘‘Have you ever tried hashish or
cannabis? If yes, at which age?’’) in survey 2009. These
surveys were sent to all adult twin families and were re-
turned by 23 597 individuals. In addition, data collection in
adolescent twins and sibs which took place since 1987 in
age-specific surveys (around age 14 and age 16), included a
multiple choice question (‘‘Have you ever used soft drugs
such as hashish or cannabis?’’) assessing frequency of use
(on an eight-category scale ranging from ‘never’ to ‘more
than 40 times’) in the whole life, in the last 12 months and
in the last 4 weeks. This question was completed by 16 556
participants. The phenotypic data obtained from subjects
who reported at more than one time point were checked for
consistency, and unreliable measures were discarded. Due
to inconsistencies, 284 self-reported measures were drop-
ped. Next, the measurements were collapsed into a di-
chotomous phenotype (i.e., ever/never used cannabis).
Furthermore, we included in the analysis only family
members for whom both phenotypes and genotypes were
available, i.e., N = 6744 participants. Of these, 5387 in-
dividuals reported never to have used cannabis, whereas
the remaining 1357 individuals had initiated cannabis use.
The age at the time of the last survey ranged from 10.5 to
94 years (mean age = 39.09, SD = 17.45). The par-
ticipants were clustered within 3479 families varying in
size from 1 to 9 family members (i.e., parents, siblings,
spouses). More than half of the sample (60.9 %) consisted
of females.
Age at onset
A subset of the genotyped NTR sample (N = 5148) had
declared never to have used cannabis, or declared an age at
onset older than 10 years of age in survey 2009 (which
included an open ended question on age at onset, see
above). Among them, 852 (16.6 %) had initiated cannabis
use, whereas 4296 observations had not initiated at the time
of data collection (i.e., censored observations). The par-
ticipants were clustered within 2992 families of sizes
varying from 1 to 8 members. Females represented 62.3 %
of the sample and the age ranged between 16 and 99 years
(mean age = 46.93, SD = 17.54).
Genotypes
Genotyping was performed based on buccal or blood DNA
samples collected in different research projects (see e.g.,
Willemsen et al. 2010). Imputation was performed based
on the 1000G GIANT phase1 panel as a first reference set,
and on the GONL version 4 as a second reference set (see
Supplementary Methods for details). As best guess geno-
types (computed using Beagle, Browning and Yu 2009)
were used in the analyses, we applied stringent post im-
putation quality thresholds on the imputation quality
measure (i.e., we retained only SNPs with an imputation
quality score above 0.8) and for the Hardy–Weinberg
equilibrium test (a = 1 9 10-4). Both the imputation
quality and Hardy–Weinberg equilibrium (i.e., based on the
summed genotype probability counts) were assessed in the
phenotyped sample using SNPTEST (Marchini, 2007). The
GoNL- and the 1000G-based imputed datasets contained
*6 million well imputed SNPs (i.e., with a mean impu-
tation quality score above 0.96 in both datasets). The as-
sociation and survival analyses were carried-out by varying
the reference panel used for imputation, while including
the same phenotyped sample (i.e., 6744 and 5148 par-
ticipants, respectively). The analyses included no
monozygotic twin pairs, because genotypic data were
available for only 1 twin of a pair in the GoNL dataset.
Statistical analyses
Estimating the heritability of initiation
We used the Genome-wide Complex Trait Analysis
(GCTA) software (Yang et al. 2011) to estimate the amount
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of variance in initiation explained collectively by the SNPs.
The aim of this analysis is to obtain an indication of the
total signal in the SNPs, without identifying individual
SNPs. Genetic similarity among the phenotyped indi-
viduals was computed based on best guess genotypes at 5
928 887 loci observed or imputed using the GoNL refer-
ence panel. The analyzed SNPs had a MAF larger than
1 %, imputation quality greater than 0.8 and showed no
significant deviation from Hardy–Weinberg equilibrium
given a = 1 9 10-4. The sample with observed initiation
status (N = 6744 related individuals of Dutch ancestry)
and the relevant covariates included in the genomewide
SNP-based analysis (see below) were also used in the
GCTA analysis. Furthermore, one of a pair of closely ge-
netically related individuals (i.e., with an estimated genetic
relatedness larger than 0.025) was dropped, which left for
the analysis 3616 distantly related individuals. We speci-
fied the prevalence as equal to 22 %, value chosen in line
with the prevalence of cannabis use estimated in Europeans
(European Monitoring Centre for Drugs and Drug Addic-
tion, 2012). Heritability of age at onset was not estimated
as GCTA cannot handle survival data. We also investigated
the relationship between chromosome length and the
amount of variance explained in the trait. Consistent with
the model of a polygenic trait, we expect—on average—
the longer chromosomes to explain a larger amount of the
variance. We tested this in a linear regression (one-tailed
test) where we regressed the estimated proportion of vari-
ance explained by each chromosome on the chromosome
length.
Power analysis
We performed a Monte Carlo power analysis to obtain an
indication on the size of the genetic effects detectable in
our sample. To this end, we simulated 10 000 samples
consisting of 3690 families of various configurations re-
flecting the unbalanced structure of families included in the
analyses, i.e., families consisting of singletons, two parents
or families comprising sibships sizes 1–6 with 0, 1 or 2
parents. Genotypes in Hardy–Weinberg equilibrium were
generated at a locus with a MAF of 0.5 and explaining 1.5
and 1 % variance in the phenotype. The normally dis-
tributed phenotype was simulated conditional on the locus
and then dichotomized using a cut-off point corresponding
to a z-score of 0.85 to mimic the 20 % prevalence of ini-
tiation observed in the NTR sample. The correlations be-
tween spouses, full siblings and parent-offspring estimated
in our sample equaled 0.39, 0.35 and 0.15, respectively. An
a = 1 9 10-8 was used to assess the power to detect as-
sociation. To model association we used a generalized
equations estimation (GEE) procedure with an exchange-
able working correlation matrix and a sandwich correction
to correct the standard errors for misspecification of the
background model (Minica et al. 2014).
Empirical power analysis showed that our sample af-
fords 45.3 and 87.4 % power to detect GVs explaining 1
and 1.5 % phenotypic variance, respectively (genomewide
alpha = 1 9 10-8). Relative to the logistic model, the
survival model is expected to show superior power espe-
cially for locating low frequency causal GVs (see e.g., van
der Net et al. 2008). However, the above power computa-
tions are informative also for the age at onset phenotype
given the large overlap among the samples included in the
two analyses and the slightly lower size of the sample we
used in the survival analysis.
SNP-based association analysis of initiation
To test association, initiation was regressed on the best
guess genotype and covariates. The covariates were sex,
age at the last survey, the birth cohort (i.e., two birth
cohorts containing individuals born between 1951 and
1970 and 1971–1999, respectively, and the 1915–1950
birth cohort as the reference category), 3 principal com-
ponents to correct for Dutch population substructure
(Abdellaoui et al. 2013), and sample specific covariates to
account for batch and for chip effects. A GEE (Carey
et al. 2012) logistic model was employed. To model the
familial relatedness, we used an exchangeable working
correlation matrix. This accounts for the familial corre-
lations by means of a single correlation among the family
members. The effect of possible misspecification of the
familial covariances on the standard errors was corrected
by means of a sandwich correction (Minica et al. 2014;
Dobson 2002). The sandwich-corrected GEE approach
was implemented by using the R-package gee (Carey
et al. 2012), accessed from Plink (Purcell et al. 2007)
which communicates with R (Team 2013) via the Rserve
package (Urbanek 2013).
SNP-based survival analysis of age at onset
A Cox proportional hazards regression model was
employed to model age at onset as a function of genotype
and—as above—of other relevant covariates (i.e., birth
cohort, sex, three PCs and study specific covariates). We
included this approach as it utilizes all available infor-
mation on the age of initiation among those who have
initiated. It is expected to show superior power relative to
an analysis of the ‘‘ever-never’’ dichotomy or an analysis
restricted to those who initiated (see e.g. Kiefer et al.
2013). The Cox proportional hazard regression analysis
was performed genomewide by accessing the survival
R-package (Therneau 2014) from Plink. In fitting the
506 Behav Genet (2015) 45:503–513
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model, we used the cluster option to get sandwich cor-
rected standard errors that are robust to possible mis-
specification of the familial covariance matrix.
Gene-based analyses of initiation and age at onset
Gene-based tests of association with initiation and age at
onset were carried out by using the gene-based association
test that employs the extended Simes procedure (GATES)
implemented in the Knowledge Based Mining System for
Genome-wide Genetic Studies software (Li et al. 2011).
Specifically, the Simes test extension was employed to
combine the P-values of SNPs belonging to the same gene.
SNPs were assigned to genes (or to genes’ vicinity, i.e.,
within a region extended 5 kb at both the 50 and at the 30
ends) according to the Human Genome version 19 refer-
ences. The LD structure was derived based on the GoNL
haplotypes and incorporated into the gene-based test as to
account for the correlatedness among SNPs within a gene.
Lacking prior significant genetic association information
related to the cannabis use phenotypes, SNPs were as-
signed equal weights in the estimation process and the
gene-based tests were conducted genomewide for both
phenotypes. There were 22 764 genes tested for association
with our phenotypes, hence for the gene-based tests the
chosen alpha level equaled 0.01/22 746 (i.e.,
*4.3 9 10-7).
Results
Estimating heritability based on genetic relatedness
Results indicate that 25 % [standard error (SE) = 0.088] of
the variance on the observed scale in initiation is explained
by the SNPs. This amount of variance explained collec-
tively by the SNPs is significantly greater than zero [i.e.,
likelihood ratio test (LRT) (degrees of freedom =
1) = 8.60, P = 0.0016]. The chromosome-by-chromo-
some heritability analysis indicated that the largest amount
of variance in the trait is explained by chromosome 4 (i.e.,
the estimate on the observed scale equaled 6.8 %,
SE = 0.025, LRT(1) = 7.93, P = 0.002). Chromosome 18
accounted for about 3.6 % (SE = 0.01) of the variance on
the observed scale in initiation (LRT(1) = 4.99,
P = 0.012).
We also investigated the relationship between chromo-
some length and the amount of variance explained (see
Supplemental Table S1 for details). We found that chro-
mosome length is significantly associated with proportion
of variance explained (one-tailed t test(20) = 1.731,
P\ 0.05). On average longer chromosomes explain a
larger percent of variance (Fig. 1).
As shown in Fig. 1, the linear trend is present,
notwithstanding the low power to detect variance compo-
nents attributable to individual chromosomes. The figure
demonstrates a trend that is likely to be stronger with in-
creasing sample size. Some parameter estimates hit the
lower bound of zero, but this is due to sampling fluctuation
(as we illustrate in a small simulation study described in the
Supplementary notes). Similar results were reported for
other complex traits like intelligence (see e.g., Davies et al.
2011).
SNP- and gene-based analyses of initiation
SNP-based P-values were obtained in two association
analyses of initiation conducted in a sample comprising
6744 participants. Two alternative reference panels—the
1000G and the GoNL, respectively—were used to impute
genotypes in our sample. Owing to a better imputation
quality (The Genome of the Netherlands 2014), the asso-
ciation signals in the GoNL imputed genotype data were
slightly stronger than those obtained based on the 1000G
imputed SNPs.1 Consequently we took forward these re-
sults for the gene-based tests. The P-values for the 5 896
100 GoNL SNPs showed no inflation i.e., the lambda in-
flation factor equaled 1.019, where a value of 1 indicates no
deviation from the expectation of the observed test statistic
due to effects of population stratification. The quantile–
quantile plot is given in Supplemental Figure S2. The most
strongly associated SNP was the low frequency GoNL SNP
rs35917943 (MAF\ 5 %; P = 1.6 9 10-7). The region
harboring this SNP is displayed in Supplemental Figure S3
(Pruim et al. 2010). Supplemental Table S2 contains the
top SNPs associated with initiation at P\ 1 9 10-5.
Table 1 contains the five genes showing the strongest as-
sociation signal with initiation along with their functions
(according to gene ontology (GO) annotations Ashburner
et al. 2000).
None of these genes had an association P-value below
our chosen genomewide level of significance of a =
4.3 9 10-7. The three genes with the lowest P-values are
Zinc Finger Protein 181 (ZNF181, P = 3.7 9 10-6), the
non-coding RNA–microRNA 643 (MIR643, P =
3 9 10-5) and the Zinc Finger Protein 766 gene (ZNF766,
1.1 9 10-4), all located on chromosome 19.
1 We include for a comparison the Manhattan plots of the association
results based on data imputed using the two alternative reference
panels (see Supplemental Figure S1). They illustrate the gains in
power—in terms of improved association signals - conferred by a
population specific reference panel relative to the 1000 Genomes.
These results are likely informative for groups contemplating the use
of alternative panels to impute GWAS samples.
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SNP- and gene-based analyses of age at onset
We conducted two genomewide survival analyses of age at
onset in a sample comprising 5148 participants. Similar to
the previous analysis, the association signals attained with
the genotypes imputed based on the GoNL reference panel
were used as input for the gene-based analysis, as these
signals were stronger relative to those observed in the
1000G imputed sample (see for a comparison the Man-
hattan plots, Supplemental Figure S4). As we observed a
slight inflation, we corrected the SNP-based P-values (ge-
nomic control k = 1.1171) to prevent potential false
positives. Supplemental Figure S5 contains the lambda
corrected quantile–quantile plots. The SNP with the
strongest association signal was the low-frequency
rs142324060 (lambda-corrected P = 7.6 9 10-8;
MAF\ 5 %). The region around the top SNP associated
with initiation—rs142324060 on chromosome 5 is dis-
played in Supplemental Figure S6. The Supplemental
Table S3 contains the top SNPs associated with age at
onset (P\ 1 9 10-5).
Table 2 includes the top five genes with the lowest
P-values obtained in the gene-based analysis alongwith their
functions (according to GO annotations).
In our exploratory gene-based analysis none of the genes
reached the genomewide significance threshold of
a = 4.3 9 10-7. The genes showing the strongest asso-
ciation with our phenotype were Gem (nuclear organelle)
associated protein 5 (GEMIN5) on chromosome 5
(P = 4.7 9 10-4) and the uncharacterized LOC101927911
on chromosome 17 (P = 4.7 9 10-4), followed by the
Metallothionein 4 (MT4) on chromosome 16 (P =
5.2 9 10-4). The SNP with the strongest association sig-
nal—the rs142324060 (lambda-corrected P = 7.6 9 10-8)
was not assigned to a gene in the GATES analysis.
Discussion
The aim of the study was to explore the contribution of
GVs to initiation of cannabis use and age at onset. Using
GCTA and a sample of distantly related individuals from
the NTR, we estimated that the genomewide SNPs col-
lectively explain 25 % (SE = 0.088; P = 0.0016) of the
variance in initiation. Although lower than the twin-based
heritability estimate (i.e., of about 44 % (95 % CI
[16 %,74 %], Vink et al. 2010), our estimate provides an
indication of the total signal in the currently measured (and
tagged) SNPs, confirming that initiation of cannabis use is
a heritable trait. The remaining variance (up to 44 %) may,
in part, be attributable to rare variants, weakly correlated
with the measured SNPs (Visscher et al. 2010). Our esti-
mate is larger than that reported by Verweij and colleagues,
namely 6 % (95 % CI [0 %, 26 %], P-value = ns). A
possible reason for this difference is that we use more
densely distributed SNPs. In addition to the common SNPs
overlapping with the HapMap SNPs used by Verweij and
colleagues (about 2.4 million common SNPs with
MAF[ 5 %), we included into analysis previously un-
tagged common GVs, and other (than common) GVs, such
as low-frequency variants (about 6 million SNPs having
MAF[ 1 %). More densely distributed SNPs are expected
to be in higher LD with the causal variants, and so, to
provide a more accurate heritability estimate (Visscher
et al. 2010).
The chromosome-by-chromosome analyses showed
that, on average, longer chromosomes account for a larger
amount of variance in initiation. This result lends support
to the conclusion that initiation is highly polygenic. The
largest amount of variance is explained by chromosome 4
(6.8 %; P = 0.002), followed by chromosome 18 (3.6 %;
P = 0.012). Regions on both chromosome 4 and 18 have
been reported to play a role in cannabis use and other
addiction phenotypes. For instance, regions on chromo-
some 4 harboring the GABRA cluster of genes were
identified in a linkage study by Agrawal et al. (Agrawal
et al. 2008b) as plausibly associated with a cannabis abuse
and dependence phenotype. Another linkage study (Pre-
scott et al. 2006) provided strong evidence for a large re-
gion on chromosome 4 to be involved in alcohol
dependence (P = 2.1 9 10-6), the same region being also
Fig. 1 Percent of variance in initiation of cannabis use explained per
chromosome relative to chromosome length. The chromosome
number is shown in circles
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Table 1 Top five genes showing the strongest association with initiation of cannabis use
Gene name (Gene ID) Chr Start
position
Number of
SNPs
assigned to
gene
Key SNPs
position (rs
number)
Gene
feature
Key SNPs
P-value
Gene
P-value
Molecular function
according to gene
ontology annotation
Zinc finger protein 181
(ZNF181)
19 35225479 2 35221228
(rs35487050)
Upstream 1.6 9 10-7 3.7 9 10-6 Nucleic acid binding;
metal ion binding
microRNA 643 (MIR643) 19 52785049 10 52787471
(rs2434422)
Intronic 3.7 9 10-6 3 9 10-5 –
52788044
(rs321908)
Intronic 8.5 9 10-6 –
Zinc finger protein 766
(ZNF766)
19 52772823 41 52787471
(rs2434422)
Intronic 3.7 9 10-6 1.1 9 10-4 Nucleic acid binding;
metal ion binding
52788044
(rs321908)
Intronic 8.5 9 10-6 –
52770905
(rs57523152)
Upstream 3.3 9 10-5 –
52790542
(rs139570481)
Intronic 2.3 9 10-4 –
52792311
(rs147711278)
Intronic 3.4 9 10-4 –
52775301
(rs2089275)
Intronic 1 9 10-2 –
Phosphatidylinositol-specific
phospholipase C, X domain
containing 2 (PLCXD2)
3 111393522 60 111416310
(rs1355767)
Intronic 1.1 9 10-6 1.1 9 10-4 Phosphoric diester
hydrolase activity
111399209
(rs7651713)
Intronic 1.2 9 10-6 –
111460129
(rs57628489)
Intronic 1.3 9 10-2 –
111430969
(rs16858448)
Intronic 1.5 9 10-2 –
111438443
(rs12637233)
Intronic 1.5 9 10-2 –
111479048
(rs7643067)
Intronic 1.6 9 10-2 –
111470751
(rs74571144)
Intronic 1.6 9 10-2 –
111463864
(rs75923425)
Intronic 1.6 9 10-2 –
111453629
(rs4682300)
Intronic 1.8 9 10-2 –
111530499
(rs138770435)
Intronic 2.7 9 10-2 –
111482694
(rs139568104)
Intronic 3 9 10-2 –
111443003
(rs9854875)
Intronic 3.2 9 10-2 –
111449944
(rs7624162)
Intronic 3.2 9 10-2 –
111514564
(rs11715999)
Intronic 4 9 10-2 –
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reported by Uhl et al. to be associated with illicit drug
abuse (Uhl et al. 2002). Regions on chromosome 18 were
suggested to harbor GVs potentially associated with ini-
tiation of cannabis use (Agrawal et al. 2008a), metham-
phetamine abuse (Lee et al. 2014) and alcohol dependence
(Prescott et al. 2006). However, when tested individually,
none of the GVs achieved an association P-value less than
the adapted (i.e., for multiple testing) alpha of 1 9 10-8.
We further explored how our results compare with
previously published ones. Using the SNP effect concor-
dance method (Nyholt 2014) and the NTR as a replication
sample, we checked whether there is an excess of SNPs
showing concordant effects in the meta-analysis by Ver-
weij et al. (2013) and in our analysis. Of the 2 110 385
HapMap SNPs tested in both samples, we selected for the
comparison 25 204 independent HapMap SNPs (r2[ 0.1)
that showed the most significant association P-values in the
meta-analysis sample. Although we compare summary
results for the same phenotype (cannabis initiation) such an
analysis is similar in scope to a search for significant
pleiotropic effects (genetic overlap): we aimed to single out
sets of SNPs showing concordant effects in the two sam-
ples beyond what is expected by chance. Concordance of
effects was assessed by exact binomial tests. We observed
no significant excess of SNPs with concordant effects in
the two datasets. It is possible that the effects of the causal
variants are too small to be accurately captured by the two
samples. It is also likely that the causal GVs were imper-
fectly tagged by the selected SNPs (e.g., because they have
a lower MAF than the selected SNPs), and this further
decreased the estimation precision in both samples.
None of the tested genes achieved genomewide sig-
nificance (P\*4.3 9 10-7). However, our results have
pinpointed several possible candidate genomic regions, likely
to have a bearing on the early stage of cannabis use. To name a
few, the ZNF181 and the ZNF766 genes, both located on
chromosome19, yielded the strongest association signal in the
gene-based analysis of initiation (i.e., P = 3.7 9 10-6,
1.1 9 10-4, respectively). According to the GO annotations,
ZNF181 and ZNF766 are functional genes belonging to the
zinc finger family of genes, being involved in nucleic acid
binding and metal ion binding. The most strongly associated
genes with age at onset were the protein coding genes
GEMIN5 (P = 4.7 9 10-4) on chromosome 5 and MT4 on
chromosome 16 (P = 5.2 9 10-4). GEMIN5 plays a role in
protein binding and snRNA binding, whereas MT4 is in-
volved in copper ion and zinc ion binding. The role these
genes play in initiation and age at onset has yet to be clarified,
as none have been previously reported to be associated with
cannabis use or other addiction phenotypes.
To our knowledge this is the first genomewide survival
analysis of age at onset of cannabis use to date. The survival
modeling approach appears to be appropriate and computa-
tionally tractable given the detailed genotypic data currently
available (an exampledataset and annotated scripts to run such
an analysis can be found at http://cameliaminica.nl/research.
php). Clearly, further research on the genetic basis of age at
onset would be of interest as the trait may serve as a proxy for
both heavy use and experimentation with other drugs.
Our study detected association signal in the measured
SNPs. A comparison with prior SNP-heritability estimates
suggests that at least part of the signal is likely coming from
previously untyped common and from low frequency vari-
ants. The lack of genomewide significant results for the
single variant and gene-based association tests suggests that
initiation is a polygenic trait characterized by variants of very
Table 1 continued
Gene name (Gene ID) Chr Start
position
Number of
SNPs
assigned to
gene
Key SNPs
position (rs
number)
Gene
feature
Key SNPs
P-value
Gene
P-value
Molecular function
according to gene
ontology annotation
Prefoldin-like chaperone
(URI1)
19 30433145 15 30511638
(rs57192507)
Downstream 2.2 9 10-5 1.8 9 10-4 Unfolded protein
binding
30465196
(rs7249169)
Intronic 2.7 9 10-5 –
30509036
(rs73924148)
Downstream 2.7 9 10-5 –
30442432
(rs77858500)
Intronic 3.1 9 10-5 –
30432202
(rs58563661)
Intronic 1.1 9 10-4 –
30418009
(rs61340893)
Intronic 2.9 9 10-2 –
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small effect (i.e.,\1 % explained phenotypic variance). The
causal variants are likely distributed over much of the gen-
ome, in proportion to the chromosomes’ length. Our results
do not rule out the contribution of rare variants of larger
effect imperfectly tracked by the measured SNPs—a plau-
sible source of the difference between the twin-based herit-
ability estimate and that from GCTA. Powerful analytic
strategies and very large samples combinedwith considering
the contribution of rare variants (MAF\ 1 %) will allow
one to further understand the causes of individual differences
in the liability to initiate cannabis use.
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